- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cetaphil Restoraderm I.R. Gel Launched by Galderma for Instant Itch Relief in Atopic Dermatitis

Galderma India has launched Cetaphil Restoraderm I.R. Gel, to provide instant itch relief in individuals with atopic dermatitis (AD)1.
Atopic dermatitis is commonly associated with persistent itching, which can trigger the itch-scratch cycle. Repeated scratching damages skin barrier, perpetuating inflammation and cytokine release that further promote itching. It can also compromise the skin barrier, contributing to ongoing inflammation and skin-barrier dysfunction2. Breaking this cycle promptly through appropriate management is therefore an important part of effective itch control.
In India, the prevalence of atopic dermatitis (AD) has been reported to be increasing, potentially influenced by changing environmental factors. Studies involving both paediatric and adult populations have reported AD prevalence ranging from 0.98% to 9.2%3. The most commonly reported symptoms include itching, dryness and sleep disturbances, with itch severity correlating with disease severity in more than 60% of patients4.
To calm the itching skin, Cetaphil Restoraderm I.R. Gel is developed as an ultra-lightweight gel, designed to have a unique cool-touch applicator with a 100% stainless-steel roller, which delivers an immediate cooling sensation and high thermal conductivity that helps reduce heat on the skin¹. The formulation is available in a patient-friendly, practical, easy-to-carry on-the-go size1.
According to Galderma, Cetaphil Restoraderm I.R. Gel provides complete itch relief within 30 seconds, with claims of itch relief lasting up to 12 hours, hydration for up to 48 hours and skin-barrier protection for up to eight hours1.
Cetaphil Restoraderm I.R. Gel contains SymCalmin® with Colloidal Oats, Ad-Resyl®, Ceramides and Filaggrin Technology™, which address itch comprehensively and support the skin barrier5.
SymCalmin® with Colloidal Oats helps to break the itch-scratch cycle by modulating neurokinin-1 receptor activation and reducing histamine release associated with the itch sensation5,6. Ad-Resyl® targets four key drivers of atopic dermatitis, including restoring skin-barrier function, supporting microbiome balance, soothing the skin, and helping calm neural hyperreactivity7,5.
Lastly, Filaggrin Technology™ delivers natural moisturising factors such as pyrrolidone carboxylic acid (PCA) and arginine, which support hydration and strengthen the skin barrier8,9,5.
Cetaphil is a dermatologist-recommended skincare brand with more than 70 years of experience, offering formulations designed for sensitive skin and skin-barrier care.
Galderma is the pure-play dermatology category leader, present in approximately 90 countries. It deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology.
IN-CET-2600930
Disclaimer: For use of registered medical practitioner only.
- 1. Galderma Data on File, Study-GLI.04.US.CS.037, Study- In use itch relief severity GLI.04.US.CS.035
- 2.Jeskey J, Kurien C, Blunk H, Sehmi K, Areti S, Nguyen D, Hostoffer R. Atopic Dermatitis: A Review of Diagnosis and Treatment.J Pediatr Pharmacol Ther.587--603
- 3.De A, Karekar S, Adhav C. Current Burden of Atopic Dermatitis in India: A Systematic Literature Review.Indian J Dermatol. 2023
- 4.Gaur K, Kothawade B, Hariharan S, Adhav CV. A Survey on the Burden and Gaps in the Management of Atopic Dermatitis: Perspectives From Indian Dermatologists.Cureus. 2025 Sep 3;17(9):e91567.
- 5. Galderma, Symrise, SILAB Data on File, Formulation claim
- 6.Lotts T, Agelopoulos K, Phan NQ, Loser K, Schmaus G, Luger TA, Ständer S. Dihydroavenanthramide D inhibits mast cell degranulation and exhibits anti-inflammatory effects through the activation of neurokinin-1 receptor.Exp Dermatol. 2017 Aug;26(8):739--742.
Deeksha Bhandari is a Medical Writer at Medical Dialogues and completed B.Sc (Hons) in Microbiology from Delhi University and PG in Food Sciences.

